1-20 of 38
Point-Counterpoint
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation

Siok-Keen Tey, Steven W. Lane
Journal: Blood Advances
Blood Adv (2022) 6 (5): 1619–1622.
https://doi.org/10.1182/bloodadvances.2021004829
Published: 2022
Journal Articles

Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation

H. Joachim Deeg
Journal: Blood Advances
Blood Adv (2022) 6 (5): 1623–1627.
https://doi.org/10.1182/bloodadvances.2021004799
Published: 2022
Journal Articles

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis

Elizabeth A. Brem, Susan O’Brien
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1361–1364.
https://doi.org/10.1182/bloodadvances.2019001204
Published: 2022
Journal Articles

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i

John F. Seymour
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1365–1370.
https://doi.org/10.1182/bloodadvances.2019001205
Published: 2022
Journal Articles

BiTEs better than CAR T cells

Marion Subklewe
Journal: Blood Advances
Blood Adv (2021) 5 (2): 607–612.
https://doi.org/10.1182/bloodadvances.2020001792
Published: 2021
Journal Articles

CAR T cells better than BiTEs

Clinical Trials & Observations
John C. Molina, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2021) 5 (2): 602–606.
https://doi.org/10.1182/bloodadvances.2020003554
Published: 2021
Journal Articles

Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute

Robert J. Soiffer
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3205–3208.
https://doi.org/10.1182/bloodadvances.2019000389
Published: 2020
Journal Articles

Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste

Bart L. Scott
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3200–3204.
https://doi.org/10.1182/bloodadvances.2019000388
Published: 2020
Journal Articles

Stem cell donors should be screened for CHIP

Amy E. DeZern, Lukasz P. Gondek
Journal: Blood Advances
Blood Adv (2020) 4 (4): 784–788.
https://doi.org/10.1182/bloodadvances.2019000394
Published: 2020
Journal Articles

Stem cell donors should not be screened for clonal hematopoiesis

Christopher J. Gibson, R. Coleman Lindsley
Journal: Blood Advances
Blood Adv (2020) 4 (4): 789–792.
https://doi.org/10.1182/bloodadvances.2019000395
Published: 2020
Journal Articles

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Guillermo F. Sanz, Mariam Ibañez, Esperanza Such
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3454–3460.
https://doi.org/10.1182/bloodadvances.2019000680
Published: 2019
Journal Articles

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Felicitas Thol, Uwe Platzbecker
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3449–3453.
https://doi.org/10.1182/bloodadvances.2018022434
Published: 2019
Journal Articles

Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details

Vaishali Sanchorawala
Journal: Blood Advances
Blood Adv (2019) 3 (2): 216–218.
https://doi.org/10.1182/bloodadvances.2018021261
Published: 2019
Journal Articles

When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression

Clinical Trials & Observations
Giovanni Palladini, Giampaolo Merlini
Journal: Blood Advances
Blood Adv (2019) 3 (2): 212–215.
https://doi.org/10.1182/bloodadvances.2018021253
Published: 2019
Journal Articles

Imatinib is still recommended for frontline therapy for CML

Clinical Trials & Observations
Andrew Hantel, Richard A. Larson
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3648–3652.
https://doi.org/10.1182/bloodadvances.2018018614
Published: 2018
Journal Articles

A second-generation TKI should always be used as initial therapy for CML

Clinical Trials & Observations
Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3653–3655.
https://doi.org/10.1182/bloodadvances.2018018655
Published: 2018
Journal Articles

Timing of treatment of smoldering myeloma: early treatment

Clinical Trials & Observations
María-Victoria Mateos, Verónica González-Calle
Journal: Blood Advances
Blood Adv (2018) 2 (21): 3045–3049.
https://doi.org/10.1182/bloodadvances.2018021220
Published: 2018
Journal Articles

Timing of treatment of smoldering myeloma: delay until progression

Clinical Trials & Observations
Shaji K. Kumar
Journal: Blood Advances
Blood Adv (2018) 2 (21): 3050–3053.
https://doi.org/10.1182/bloodadvances.2018021238
Published: 2018
Journal Articles

Emicizumab should be prescribed independent of immune tolerance induction

Sandra Le Quellec, Claude Negrier
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2783–2786.
https://doi.org/10.1182/bloodadvances.2018015859
Published: 2018
Journal Articles

Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance

Guy Young
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2780–2782.
https://doi.org/10.1182/bloodadvances.2018015842
Published: 2018